MEI Pharma, Inc. (MEIP)

NASDAQ: MEIP · IEX Real-Time Price · USD
0.486
0.020 (4.21%)
At close: May 20, 2022 4:00 PM
0.485
-0.001 (-0.124%)
After-hours:May 20, 2022 7:44 PM EDT
Market Cap64.58M
Revenue (ttm)44.14M
Net Income (ttm)-54.68M
Shares Out132.99M
EPS (ttm)-0.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,885,695
Open0.466
Previous Close0.466
Day's Range0.449 - 0.489
52-Week Range0.450 - 3.550
Beta1.27
AnalystsBuy
Price Target5.41 (+1,014.1%)
Earnings DateMay 26, 2022

About MEIP

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and ...

IndustryBiotechnology
IPO DateDec 19, 2003
CEODaniel Gold
Employees76
Stock ExchangeNASDAQ
Ticker SymbolMEIP
Full Company Profile

Financial Performance

In 2021, MEI Pharma's revenue was $25.54 million, a decrease of -11.68% compared to the previous year's $28.91 million. Losses were -$50.58 million, 9.91% more than in 2020.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for MEIP stock is "Buy." The 12-month stock price forecast is 5.41, which is an increase of 1,014.09% from the latest price.

Price Target
$5.41
(1,014.09% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to ...

Los Angeles, California--(Newsfile Corp. - May 19, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MEI Pha...

2 days ago - Newsfile Corp

MEI ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages...

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MEI Pharma, Inc. (“MEI” or the “Company”)...

2 days ago - Business Wire

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact...

Los Angeles, California--(Newsfile Corp. - May 18, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MEI Pha...

3 days ago - Newsfile Corp

MEI PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Enc...

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MEI Pharma, Inc. (“MEI” or the “Company”)...

3 days ago - Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MEI Pharma, Inc. (MEIP) ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MEI Pharma, Inc. (“...

3 days ago - Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of MEI Pharma, Inc. (“MEI Pharma” or the “Company”) (NASDAQ: MEIP) investors concerning the Company's ...

4 days ago - Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Conta...

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm

4 days ago - Business Wire

MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright G...

4 days ago - Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of MEI Pharma, Inc. (“MEI Pharma” or the “Company”) (NASDAQ: MEIP) on behalf of investors concerning the Company...

4 days ago - Business Wire

Rosen Law Firm Encourages MEI Pharma, Inc. Investors with Losses to Inquire About Class Action Investigation – MEIP

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MEI Pharma, Inc. (NASDAQ: MEIP) ...

4 days ago - Business Wire

MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Associati...

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151)...

1 week ago - Business Wire

10 Top Penny Stocks To Buy For Under $1 May 2022 Edition

Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

2 weeks ago - PennyStocks

MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for ...

2 weeks ago - Business Wire

MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two posters presenting preclinical da...

1 month ago - Business Wire

5 Penny Stocks To Buy According To Big Money Options Bets Right Now

Penny stocks with interesting options activity today. The post 5 Penny Stocks To Buy According To Big Money Options Bets Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...

Other symbols:BBIGCEICLVRSNDL
1 month ago - PennyStocks

Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug

Mei Pharma's (MEIP) FDA filing plans for zandelisib for lymphoma indication get derailed after the agency requests more clinical studies. The stock plummets in after-market trading post this news.

1 month ago - Zacks Investment Research

Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update

The FDA crushed MEI Pharma Inc's (NASDAQ: MEIP) hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 data. In the meeting, the FDA informed that a randomi...

1 month ago - Benzinga

Penny Stocks Today: Why MEIP and HNST Are Plunging Friday

We're checking in on the latest penny stocks news for today with two companies that investors are watching fall on Friday! The post Penny Stocks Today: Why MEIP and HNST Are Plunging Friday appeared fir...

Other symbols:HNST
1 month ago - InvestorPlace

Why MEI Pharma Stock Is Plummeting After Hours

MEI Pharma Inc (NASDAQ: MEIP) shares are plunging in Thursday's after-hours session after the company provided an investor update following a recent meeting with the U.S. Food and Drug Administration. D...

1 month ago - Benzinga

MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today provided an update after a recent meeting with the U.S. Food Drug Administra...

1 month ago - Business Wire

MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AA...

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two abstracts highlighting data from ...

2 months ago - Business Wire

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates

MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 31.58% and 139.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, ...

3 months ago - Business Wire

MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the expansion of its management team with ...

3 months ago - Business Wire

Will MEI Pharma, Inc. (MEIP) Report Negative Q2 Earnings? What You Should Know

MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research